Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Эволокумаб и клинические исходы у пациентов с сердечно-сосудистыми заболеваниями
2017-03-17
SCID: 54.1/cr6ur8gn
Discuss with AI
EvolocumabFOURIER randomized placebo-controlled trialPCSK9 inhibitionatherosclerotic cardiovascular diseaselow-density lipoprotein (LDL) cholesterol reduction
Figures from the paper
Abstract (AI)
BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. RESULTS: At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter [1.9 mmol per liter]). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). CONCLUSIONS: In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. (Funded by Amgen; FOURIER ClinicalTrials.gov number, NCT01764633 .).
Key Findings
1
Adverse events were similar between groups except injection-site reactions were more common with evolocumab (2.1% vs 1.6%); no significant increase in new-onset diabetes or neurocognitive events.
2
Benefits were consistent across key subgroups, including patients in the lowest quartile of baseline LDL (median 74 mg/dL).
3
Evolocumab reduced LDL cholesterol by 59% at 48 weeks versus placebo, from a median 92 mg/dL to 30 mg/dL (P<0.001).
4
Evolocumab significantly reduced the key secondary endpoint (cardiovascular death, myocardial infarction, or stroke): 5.9% vs 7.4% (hazard ratio 0.80; 95% CI 0.73–0.88; P<0.001).
5
Evolocumab significantly reduced the primary composite cardiovascular endpoint (9.8% vs 11.3%; hazard ratio 0.85; 95% CI 0.79–0.92; P<0.001).
Research Object
Patients with atherosclerotic cardiovascular disease receiving statin therapy enrolled in the evolocumab randomized controlled trial
Research Subject
Effect of evolocumab (PCSK9 inhibition) on LDL cholesterol reduction and prevention of major cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization)
Publication Details
Publication Date
2017-03-17
Journal
Publisher
ISSN
Cited by
6127
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by19
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease2017
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk2019
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2019
2023 ESC Guidelines for the management of acute coronary syndromes2023
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2020
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2019
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)2017
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association2021
Colchicine in Patients with Chronic Coronary Disease2020
Evinacumab for Homozygous Familial Hypercholesterolemia2020
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease2019
2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines2022
Ten things to know about ten cardiovascular disease risk factors – 20222022
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia2026
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk2022
Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention2025
Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the US2024